Cutaneous Adverse Drug Reactions

我们继续评估有皮肤药物不良反应（如药物过敏综合征）的患者，包括与分子靶向治疗相关的有皮肤毒性发展风险的患者。这些评估包括治疗开始前的基线评估和监测和治疗这些皮肤毒性的随访。我们之前已经并将继续与肿瘤学同事合作，a)优化设计治疗方案，以评估和治疗皮肤毒性，b)通过多次同行评审的出版物和内部和外部讲座，向研究团体通报潜在的新描述的皮肤毒性和管理这些不良反应的方法，以优化肿瘤患者的持续抗肿瘤治疗。

We have continued to evaluate patients with cutaneous adverse drug reactions (e.g. drug hypersensitivity syndromes) including patients at risk for the development of cutaneous toxicities associated with molecularly targeted therapies. These evaluations include baseline evaluations prior to initiation of treatment and follow-up visits to monitor and treat these skin toxicities. We previously have worked and continue to work with oncology colleagues a) to optimally design treatment protocols to evaluate for and treat cutaneous toxicities, and b) to inform the research community of potentially newly described skin toxicities and methods for management of these adverse effects to optimize continued antineoplastic treatment of oncology patients through multiple peer-reviewed publications and lectures intramurally and extramurally.